Pharvaris (PHVS) Expected to Announce Earnings on Wednesday

Key Points

• Pharvaris (NASDAQ:PHVS) is expected to report its Q1 2025 earnings results on August 13th, with analysts forecasting losses of ($0.87) per share.
• The company missed previous earnings expectations, reporting ($0.89) EPS in its last quarter, and analysts project $-3 EPS for both the current and next fiscal years.
• Pharvaris has a consensus rating of Buy and an average price target of $36.20, with several firms issuing positive ratings and price targets up to $32.00.

Pharvaris (NASDAQ:PHVS - Get Free Report) is expected to be announcing its Q1 2025 earnings results before the market opens on Wednesday, August 13th. Analysts expect Pharvaris to post earnings of ($0.87) per share for the quarter.

Pharvaris (NASDAQ:PHVS - Get Free Report) last posted its quarterly earnings data on Tuesday, May 13th. The company reported ($0.89) earnings per share for the quarter, missing analysts' consensus estimates of ($0.80) by ($0.09). On average, analysts expect Pharvaris to post $-3 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Pharvaris Trading Down 4.3%

NASDAQ:PHVS traded down $0.91 during midday trading on Thursday, reaching $20.32. The company had a trading volume of 93,425 shares, compared to its average volume of 218,178. Pharvaris has a 12-month low of $11.51 and a 12-month high of $26.33. The stock's fifty day simple moving average is $19.06 and its 200-day simple moving average is $17.11.

Analyst Ratings Changes

Several research analysts have recently issued reports on PHVS shares. Cantor Fitzgerald lowered their target price on shares of Pharvaris from $28.00 to $25.00 and set an "overweight" rating for the company in a report on Wednesday, May 14th. Guggenheim initiated coverage on Pharvaris in a report on Wednesday, June 11th. They set a "buy" rating and a $32.00 price objective on the stock. Finally, Wedbush reissued an "outperform" rating and issued a $27.00 target price on shares of Pharvaris in a research report on Thursday, June 5th. Five equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock has an average rating of "Buy" and a consensus price target of $36.20.

About Pharvaris

Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks which is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients which is under Phase 1 clinical trial.